Abera Bioscience AB

Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.

Quotes for Abera Bioscience AB

Board

CEO

Maria Alriksson

Chairperson of the Board

Anders Ericsson

Board

Cristina Glad
Fredrik Juserius
Harry Råstedt
Mats Wahlström

Articles of association

Videos

1 / 2

CompanyPresentation Abera Bioscience – Stora Aktiedagarna Stockholm 10 mars 2026

ProductNews Abera's vaccine platform BERA - short explanation

** Powered by Modular Finance

*Powered by Modular Finance

Key Numbers

	2026-03-31	2025-12-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Number of months that the report spans	Q1 3 Months	2025	Q4 3 Months	Q3 3 Months	Q2 3 Months	Q1 3 Months	2024
Total revenue MSEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings before interest and tax MSEK	-5.83	-10.58	-8.87	-0.87	-0.84	0.00	-1.12
Profit before tax MSEK	-5.80	-10.45	-8.80	-0.84	-0.83	0.01	-1.10
Net profit MSEK	-5.80	-10.45	-8.80	-0.84	-0.83	0.01	-1.10
Earnings per share SEK	-0.29	-0.63	-0.53	-0.05	-0.05	0.00	-0.07
Dividend per share SEK	0,00	0.00	0,00	0,00	0,00	0,00	0.00
Equity MSEK	23.49	19.29	19.29	28.08	7.77	8.67	8.66
Fixed assets MSEK	1.24	1.30	1.30	1.29	1.05	1.03	1.07
Intangible assets MSEK	1.89	1.89	1.89	1.89	1.89	1.89	1.89
Current assets MSEK	27.92	25.37	25.37	29.69	10.99	8.72	10.65
Total asset MSEK	31.05	28.57	28.57	34.07	13.92	11.64	13.60
Long term liabilities MSEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current liabilities MSEK	7.57	9.28	9.28	5.99	6.15	2.97	4.95
Number of shares SEK	20498949.00	18629790.00	18629790.00	18629790.00	15352350.00	15352350.00	15352350.00